SEC Filing Summary: Form 8-K
Business Context and Reporting Period
Company: ADVENTRX Pharmaceuticals, Inc. (Note: Metadata referenced Savara Inc, but filing text identifies ADVENTRX Pharmaceuticals, Inc.)
Date: January 4, 2010
Event: Submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the product candidate ANX-530 (vinorelbine injectable emulsion).
Financial Metrics
This filing is a Current Report (Form 8-K) regarding a specific corporate event. It does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metric.
Material Changes
The material change reported is the regulatory milestone of submitting an NDA for ANX-530. No financial or operational changes compared to a prior period are detailed in this document.
Outlook, Risks, and Management Commentary
Management Commentary: The company announced the NDA submission via a press release (Exhibit 99.1).
Risks/Contingencies: The filing does not explicitly list risks or contingencies, though the submission of an NDA inherently involves regulatory review risks not detailed in this specific text.
Key Facts for Investor Verification
- Verify the status of the NDA for ANX-530 (vinorelbine injectable emulsion) with the FDA.
- Review the attached press release (Exhibit 99.1) for detailed product information and potential timelines.
- Confirm the company's current financial position through its most recent 10-K or 10-Q filings, as this 8-K contains no financial data.
- Note the discrepancy between the metadata company name (Savara Inc) and the registrant name in the filing (ADVENTRX Pharmaceuticals, Inc).